Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atamparib in Advanced NSCLC (PARP7)
ChiCTR2600117616Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atamparib in Non-small cell lung cancer adenocarcinoma (NSCLC) and Nonhematologic neoplasms (5 arms), sponsored by Shanghai East Hospital. Primary endpoints: Overall safety profile of atamparib and Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
atamparib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2600117616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117616.